HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jan Marini Focused On Damage Control Following FDA Seizure Of Eyelash Item

This article was originally published in The Rose Sheet

Executive Summary

Jan Marini issued a statement Nov. 16 stressing that its Age Intervention Eyelash product has not been manufactured or distributed since September of last year, in response to a release from FDA announcing seizure of the "potentially harmful" product

You may also be interested in...



European Commission Examining Prostaglandins In Cosmetics: Are They Safe? Are They Drugs?

Marketers of cosmetic products that rely on prostaglandins or their analogues to grow eyelashes – or compete against companies that use the ingredients – have until 22 October to submit information to the Commission, which will help inform an assessment by the Scientific Committee on Consumer Safety.

Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Marketers of cosmetic lash enhancers that haven’t abandoned prostaglandin analogs in favor of peptides or botanical extracts should take heed of a proposed class action against Rodan + Fields in California’s Northern District. Plaintiffs say they would not have purchased the firm’s Lash Boost and suffered alleged adverse effects if they’d been properly informed about product risks.

Former FDA Cosmetics Director Weighs In On Senator Hatch's Draft FCSMA

Under the draft FDA Cosmetic Safety and Modernization Act, a product could be deemed adulterated "regardless of whether it is known which particular substance or substances may render the cosmetic injurious." EAS Consulting Group's John Bailey offers his perspective on the provision and the overall bill in an exchange with the Rose Sheet.

Related Content

UsernamePublicRestriction

Register

RS015094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel